Control Bionics Boosts Capital to $9.75 Million with Completed Share Purchase Plan
Control Bionics has closed its Share Purchase Plan, raising $256,500 and pushing total capital raised to $9.75 million, pending shareholder approval for the final tranche.
- SPP raised $256,500 at 7.5 cents per share
- Total capital raise including placement reaches $9.75 million
- Placement split into two tranches, second pending shareholder approval
- 3.42 million new shares issued under SPP
- Funds to support strategic growth in neurotechnology markets
Share Purchase Plan Completes with $256,500 Raised
Control Bionics Limited (ASX:CBL) has wrapped up its Share Purchase Plan (SPP), securing $256,500 from shareholders at an issue price of 7.5 cents per share. This modest but meaningful contribution brings the company’s total capital raised, including a recent placement, to $9.75 million. The SPP issued 3,419,993 new shares, which are expected to start trading on the ASX imminently.
Placement Funding Split Across Two Tranches
The $9.75 million raise includes a two-tranche placement: the first tranche of $2.25 million has already been received, while the second tranche of $7.25 million awaits shareholder approval at the upcoming General Meeting scheduled for 6 August 2026. The finalisation of this second tranche remains a key milestone for Control Bionics’ funding strategy.
Investor Composition and Strategic Implications
Of the total funds raised, $6.1 million came from new investors, signalling continued external interest in Control Bionics’ neurotechnology platform. Existing shareholders contributed $3.65 million through the SPP and placement, reflecting ongoing confidence in the company’s growth trajectory. Control Bionics aims to leverage this capital to advance its noninvasive neural-signal technology across assistive communication, sports performance, rehabilitation, and medical research markets.
Technology and Market Position
Control Bionics’ technology captures physiological signals with medical-grade precision without requiring surgical implantation, holding regulatory clearances in key markets including the US, Australia, and Europe. The company is expanding beyond its established assistive communication applications into broader human-computer interface domains, which may benefit from the fresh capital injection.
Bottom Line?
The upcoming shareholder vote on the $7.25 million tranche will be pivotal in determining the full extent of Control Bionics’ funding runway and ability to execute its growth plans.
Questions in the middle?
- Will shareholders approve the second tranche of the $7.25 million placement?
- How will the new capital be allocated across Control Bionics’ diverse market applications?
- What impact will this raise have on the company’s valuation and investor sentiment?
